Table 1:
Study Characteristics of Patients with or without Cardiotoxicity on Protocol
| Overall N=33 |
No Cardiotoxicity N=30 |
Cardiotoxicity* N=3 |
||
|---|---|---|---|---|
| Demographics | ||||
| Age (yrs), Median (IQR) | 65 (60–68) | 64.5 (58–69) | 65 (62–68) | |
| Age range (yrs) | 35–79 | 35–79 | 62–68 | |
| Female, N (%) | 18 (54.6) | 17 (56.7) | 1 (33.3) | |
| Race, N (%): | ||||
| Black | 5 (15.2) | 4 (13.3) | 1 (33.3) | |
| Caucasian | 28 (84.9) | 26 (86.7) | 2 (66.7) | |
| Cancer History and Anthracycline Dosing | ||||
| Time since Diagnosis (days), Median (IQR) | 115 (43–279) | 141 (46–279) | 43 (28–405) | |
| Prior Chemotherapy | 3 (9.1) | 3 (10.0) | 0 (0) | |
| Prior Chest Radiation | 1 (3.0) | 1 (3.3) | 0 (0) | |
| Doxorubicin Dosing on Study | ||||
| # of cycles, Median (IQR) | 6 (4–10) | 5.5 (4–10) | 9 (8–16) | |
| Total Dose (mg/m2), Median (IQR) | 450 (300–750) | 412.5 (300–750) | 675 (600–1200) | |
| Baseline Cardiac Function | ||||
| Baseline LVEF, Median (IQR) | 65 (60–69) | 65 (60–71) | 68 (48–68) | |
| LVEF < 50%, N (%) | 1 (3.0)** | 0 (0) | 1 (33.3)** | |
| Absolute Baseline strain (GLS), Median (IQR) | 18.8 (16.8–20) | 19.23§ (16.8–20.1) | 17.2 (13.2–18.5) | |
| Baseline Comorbidities | ||||
| Diabetes Mellitus, N (%) | 6 (18.2) | 6 (20.0) | 0 (0.0) | |
| Hyperlipidemia, N (%) | 17 (51.5) | 15 (50.0) | 2 (66.7) | |
| Hypertension, N (%) | 23 (69.7) | 31 (70.0) | 2 (66.7) | |
| Tobacco use, N (%) | 11 (33.3) | 10 (33.3) | 1 (33.3) | |
| Heart Failure (Systolic), N (%) | 2 (6.1) | 1 (3.3) | 1 (33.3) | |
| Arrhythmia, N (%) | 4 (12.1) | 4 (13.3) | 0 (0) | |
| CAD, including coronary calcifications | 9 (27.3) | 8 (26.7) | 1 (33.3) | |
| Obstructive CAD, N (%) | 1 (3.0) | 1 (3.3) | 0 (0.0) | |
| CAD, HF, or any CV risk factor, N (%) | 28 (84.9) | 25 (83.3) | 3 (100) | |
| eGFR (Creatinine), Median (IQR) | 88.4 (68.1–101.9) | 87.6 (68.1–101.9) | 90.0 (52.4–107.2) | |
| Baseline Cardiac Medications | ||||
| Beta-blocker | 6 (18.2) | 5 (16.7) | 1 (33.3) | |
| ACE-I/ARB | 13 (39.4) | 12 (40.0) | 1 (33.3) | |
| Aldosterone Antagonist | 0 (0) | 0 (0) | 0 (0) | - |
| Statin | 11 (33.3) | 10 (33.3) | 1 (33.3) | |
| Aspirin | 12 (36.4) | 11 (36.7) | 1 (33.3) | |
*
3 patients removed from study for cardiotoxicity including one with baseline LVEF <50% and two with LVEF decline >10% to less than 50%. No patients required HF hospitalization while on study.
**
The patient with a baseline LVEF of 47% (asymptomatic) is the same one reported to have cardiotoxicity.
§
3 patients missing baseline strain from No Cardiotoxicity group
Obstructive CAD: prior positive stress, PCI, CABG or MI)